Don Soland
Fortune : 953 928 $ au 31/05/2026
Fortune : 953 928 $ au 31/05/2026
Daniel B. Soland was Director-Worldwide Marketing Operations & VP at Corixa Corp.
from 1993 to 2002.
Served as President & Chief Executive Officer at Epigenesis Pharmaceuticals LLC from 2002 to 2005.
Held the position of President at Seqirus Vaccines Ltd. from 2005 to 2006.
Was President-Chiron Vaccines at Chiron Corp.
from 2005 to 2006.
Chief Operating Officer & Senior Vice President at Viropharma, Inc. from 2008 to 2014.
Chief Operating Officer & Senior Vice President at Shire ViroPharma, Inc. from 2008 to 2014.
Chief Executive Officer & Executive Director at uniQure NV in 2016.
Independent Director at ACADIA Pharmaceuticals, Inc. from 2015 to 2025.
Independent Director at DBV Technologies SA from 2015 to 2025.
Non-Executive Director at Oxford Biomedica Plc from 2015 to 2016.
Independent Director at KalVista Pharmaceuticals, Inc. from 2019 to 2022.
Chief Operating Officer & Senior Vice President at Idera Pharmaceuticals, Inc. from 2020 to 2022.
Director at Tarsa Therapeutics, Inc. Education includes undergraduate studies at the University of Iowa.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 29/05/2025 | 44 041 ( 0,03% ) | 953 928 $ | 31/05/2026 |
| Sociétés | Poste | Fin |
|---|---|---|
| ACADIA PHARMACEUTICALS INC. | Directeur/Membre du Conseil | 30/10/2025 |
| DBV TECHNOLOGIES | Directeur/Membre du Conseil | 18/09/2025 |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Directeur des opérations | 28/09/2022 |
| KALVISTA PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 26/05/2022 |
| UNIQURE N.V. | Directeur Général | 22/09/2016 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 14 |
|---|---|
Chiron Corp.
Chiron Corp. Medical SpecialtiesHealth Technology Provides nucleic acid test for blood screening | Health Technology |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Health Technology |
Shire ViroPharma, Inc.
Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs | Health Technology |
Corixa Corp.
Corixa Corp. BiotechnologyHealth Technology Develops and manufactures oncology and immunology products | Health Technology |
ACADIA Pharmaceuticals, Inc.
ACADIA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals drugs for treatment of central nervous system disorders | Health Technology |
Seqirus Vaccines Ltd.
Seqirus Vaccines Ltd. BiotechnologyHealth Technology Manufactures vaccines | Health Technology |
Oxford Biomedica Plc
Oxford Biomedica Plc BiotechnologyHealth Technology Operates as a contract development and manufacturing organization which provides viral vectors to pharmaceutical and biotechnology clients in cell and gene therapy fields | Health Technology |
University of Iowa
University of Iowa Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Epigenesis Pharmaceuticals LLC
Epigenesis Pharmaceuticals LLC Pharmaceuticals: OtherHealth Technology Develops inhaled respiratory medicines | Health Technology |
DBV Technologies SA
DBV Technologies SA Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that focuses on changing the field of immunotherapy | Health Technology |
Tarsa Therapeutics, Inc.
Tarsa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel oral treatment for post-menopausal osteoporosis | Health Technology |
uniQure NV
uniQure NV BiotechnologyHealth Technology Engages in the discovery, development and commercialization of gene therapies products | Health Technology |
KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets small molecule protease inhibitors for diseases | Health Technology |
Viropharma, Inc. |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national